FDA Grants Priority Review to Takeda's Zasocitinib for Psoriasis Treatment

The U.S. FDA has accepted Takeda's New Drug Application for zasocitinib, an oral TYK2 inhibitor, targeting moderate-to-severe plaque psoriasis. The drug received Priority Review status, signaling the FDA's intent to make a decision within six months. This development could potentially offer a new oral treatment option for patients, impacting future therapeutic approaches for the condition.